 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning CEL-SCI Corporation
|
-
CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
(08/16/2007)
Biomedical Real Estate Group Backs Construction of Facility
CEL-SCI Corporation announced that it has entered into an agreement with a biomedical real estate group under which CEL-SCI acquires long term use of a dedicated manufacturing facility for its cancer drug Multikine(R). The financial value of this ...
-
CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
(05/29/2007)
CEL-SCI CORPORATION announced that CEL-1000 increased the immune response against H5 avian influenza antigen in combination with MAS-1, a water-in-oil adjuvant delivery system. These findings were presented at the American Society of Microbiologists ...
-
CEL-SCI Announced Issuance of U.S. Patent for New Platform Technology to Treat Immune System-Based Diseases
(04/30/2007)
CEL-SCI Corporation announced the issuance of a U.S. patent for a new platform technology. This technology can be used for the treatment of a number of major diseases including autoimmune disease, asthma, allergy and transplant rejection. This ...
-
CEL-SCI Receives Green Light From FDA to Proceed With Phase III Cancer Study
(01/18/2007)
CEL-SCI Corporation announced that the U.S. Food and Drug Administration (FDA) has stated in a letter to the Company that, "...the proposed Phase III study may proceed at any time." CEL-SCI's Phase III clinical study is designed to prove that its ...
-
CEL-1000 Peptide Shows Adjuvant Activity with Malaria Vaccines
(04/21/2006)
CEL-SCI Corporation announced that its CEL-1000 peptide showed adjuvant activity when used with a peptide based malaria vaccine and a DNA based malaria vaccine in animal challenge studies as part of a Cooperative Research arrangement with the Naval ...
-
CEL-SCI Signs Agreement With U.S. Government Institute for Testing of Drug Against Avian Flu Virus H5N1
(12/07/2005)
CEL-SCI CORPORATION has signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI's patented anti-infective drug ...
-
CEL-1000 Peptide Effective Against Viral Encephalitis in Mice
(04/06/2005)
CEL-SCI CORPORATION announced that its CEL-1000 immune-modulating peptide was shown in mice to protect against viral encephalitis, a potentially lethal inflammation of the brain. Viral encephalitis is on the U.S. government's list of priority ...
-
CEL-SCI reports on adjuvant properties of CEL-1000 peptide to enhance vaccines
(06/06/2003)
Zimmerman: "CEL-1000 does not appear to induce self- directed or cross-reactive antibodies, can be well characterized and is inexpensive to manufacture."
Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology at CEL-SCI Corporation today reported at the conference Modern Vaccines, Adjuvants and Delivery Systems in Dublin, Ireland on the potential use of the Company's CEL-1000 ...
|
|
|
|
|
Top